| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Peter C. Brandt is Director at INAB. Peter C. Brandt's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $90K at current prices.
Net of sales, the INAB filings show accumulation of 105,263 shares.
Peter C. Brandt has 17 Form 4 filings on record from September 2015 to May 2026, across 2 companies: Director at IN8bio (INAB), 2021–2026; Director at Opus Genetics (IRD), 2015–2019.
The 27 reported transactions were 18 option or other derivative awards, 3 stock awards, 3 dispositions back to the company and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $200K and no sales.
The only open-market purchase was 105,263 shares of INAB at an average $1.90 on August 16, 2022, about $200K. Twelve months later INAB was down 37%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | INAB In8bio, Inc. | Director | Buy | 105,263 | $1.90 | $199,999.70 | +136.3% | -19.6% | -37.0% |